Kim Min Soo, Park Eun Suk, Park Jun Bum, Lyo In Uk, Sim Hong Bo, Kwon Soon Chan
Department of Neurosurgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
J Korean Neurosurg Soc. 2018 Mar;61(2):201-211. doi: 10.3340/jkns.2017.0303.009. Epub 2018 Feb 28.
The purpose of this study was to analyze the variability of clopidogrel responses according to duration of a clopidogrel drug regimen after stent-assisted coil embolization (SAC), and to determine the correlation between the variability of clopidogrel responses and thromboembolic or hemorrhagic complications.
A total of 47 patients who underwent SAC procedures to treat unruptured intracranial aneurysms were enrolled in the study. Preoperatively, patients received more than seven days of aspirin (100 mg) and clopidogrel (75 mg), daily. P2Y12 reaction unit (PRU) was checked with the VerifyNow test one day before the procedure (pre-PRU) and one month after the procedure (post-PRU). PRU variability was calculated as the difference between the initial response and the follow-up response. Patients were sorted into two groups based on their response to treatment : responsive and hypo-responsive.
PRU variability was significantly greater in the hypo-responsive group when compared to the responsive group (=0.019). Pre-PRU and serum platelets counts were significantly correlated with PRU variation (=0.005 and =0.004, respectively). Although thromboembolic complication had no significant correlated factors, hemorrhagic complication was correlated with pre-PRU (=0.033).
In conclusion, variability of clopidogrel responses during clopidogrel medication was correlated to serum platelet counts and the initial clopidogrel response. Thromboembolic and hemorrhagic complications did not show correlation with the variability of clopidogrel response, or the clopidogrel response after one month of medication; however, hemorrhagic complication was associated with initial clopidogrel response. Therefore, it is recommended to test patients for an initial clopidogrel response only, as further tests would be insignificant.
本研究旨在分析支架辅助弹簧圈栓塞术(SAC)后氯吡格雷治疗方案持续时间与氯吡格雷反应变异性之间的关系,并确定氯吡格雷反应变异性与血栓栓塞或出血并发症之间的相关性。
本研究共纳入47例行SAC治疗未破裂颅内动脉瘤的患者。术前,患者每天接受超过7天的阿司匹林(100mg)和氯吡格雷(75mg)治疗。在手术前一天(术前PRU)和手术后一个月(术后PRU)使用VerifyNow检测法检查P2Y12反应单位(PRU)。PRU变异性计算为初始反应与随访反应之间的差异。根据患者对治疗的反应将其分为两组:反应性组和低反应性组。
与反应性组相比,低反应性组的PRU变异性显著更大(P=0.019)。术前PRU和血清血小板计数与PRU变化显著相关(分别为P=0.005和P=0.004)。虽然血栓栓塞并发症没有显著的相关因素,但出血并发症与术前PRU相关(P=0.033)。
总之,氯吡格雷用药期间氯吡格雷反应的变异性与血清血小板计数和初始氯吡格雷反应相关。血栓栓塞和出血并发症与氯吡格雷反应变异性或用药一个月后的氯吡格雷反应无关;然而,出血并发症与初始氯吡格雷反应相关。因此,建议仅对患者进行初始氯吡格雷反应检测,因为进一步检测将无意义。